Study for Predictors of Effectiveness in Tocilizumab Therapy (PETITE)

Study for Predictors of Effectiveness in Tocilizumab Therapy (PETITE) - PETITE study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002246

Enrollment

Registered

2009-08-01

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were resistant for DMARDs (including MTX) or anti-TNF biologics therapy, and then will receive tocilizumab therapy

Exclusion criteria

Exclusion criteria: Patients who received tocilizumab therapy previously Patients who received steroid newly, dose-up of steroid, plasma exchange or artificial joint replacements within 4 weeks before tocilizumab treatment

Design outcomes

Primary

Measure	Time frame
DAS28 and CDAI at 12 week after the start of tocilizumab therapy	—

Secondary

Measure	Time frame
DAS28 and CDAI at 28 week after the start of tocilizumab therapy Adverse event	—

Countries

Japan

Contacts

Public Contacttatsuya Koike

Osaka City University Medical School Center for Senile Degerative Disorders (CSDD)

tatsuya@med.osaka-cu.ac.jp6+6646-6010

Outcome results